ChemicalBook > Product Catalog >API >Antineoplastic agents >Other antineoplastic Drugs >MGA271

MGA271

Request For Quotation
MGA271 Suppliers list
Company Name: TargetMol Chemicals Inc.
Tel: +1-781-999-5354; +1-00000000000
Email: marketing@targetmol.com
Products Intro: Product Name:Enoblituzumab
CAS:1353485-38-7
Purity:SDS-PAGE:96.3%;SEC-HPLC:98.5% Package:1mg;195USD|5mg;483USD|10mg;692USD
Company Name: Aladdin Scientific
Tel:
Email: tp@aladdinsci.com
Products Intro: Product Name:Enoblituzumab (anti-CD276)
CAS:1353485-38-7
Purity:Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human I Package:$69.9/100μg;$319.9/1mg;$779.9/5mg;$1239.9/10mg;Bulk package Remarks:Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
Company Name: BOC Sciences  
Tel: 1-631-485-4226; 16314854226
Email: info@bocsci.com
Products Intro: Product Name:MGA271
CAS:1353485-38-7
Remarks:Reach out to us for more information about custom solutions.
Company Name: Shanghai YuanYe Biotechnology Co., Ltd.  
Tel: 13636370518
Email: shyysw007@163.com
Products Intro: Product Name:Enoblituzumab (anti-CD276)
CAS:1353485-38-7
Purity:ExactAb?, Validated, Carrier Free, Low Endotoxin, Azide Free Package:5mg Remarks:K10774
Company Name: ShangHai Biochempartner Co.,Ltd  
Tel: 177-54423994 17754423994
Email: 2853530910@QQ.com
Products Intro: Product Name:Enoblituzumab
CAS:1353485-38-7
Purity:95% Package:100ug;500ug;1mg

MGA271 manufacturers

  • Enoblituzumab
  • Enoblituzumab pictures
  • $195.00
  • 2026-07-13
  • CAS:1353485-38-7
  • Purity: 95.00%
  • Supply Ability: 10g
MGA271 Basic information
Product Name:MGA271
Synonyms:MGA271;Research Grade Enoblituzumab(DHJ04001);Enoblituzumab (anti-CD276);MGA271|||TJ-271;Research Grade Enoblituzumab;Enoblituzumab
CAS:1353485-38-7
MF:
MW:0
EINECS:
Product Categories:
Mol File:Mol File
MGA271 Structure
MGA271 Chemical Properties
form Liquid
color Colorless to light yellow
Safety Information
MSDS Information
MGA271 Usage And Synthesis
UsesEnoblituzumab (MGA271) is a humanized IgG1κ monoclonal antibody recognizing human B7-H3 protein, a member of the B7 family of immune regulators[1].
in vivo

Enoblituzumab (5 mg/kg; i.v.; single dose) exhibits estimated half-life of 249 hours with a Cmax of 43 mg/mL in mice (mCD16-/-hCD16A+) that murine CD16 gene knocked out and are transgenic for human CD16A-158F[3].
Enoblituzumab (0.1-10 mg/kg; i.v.; once weekly; 5 weeks) exhibits potent antitumor activity in B7-H3-expressing xenograft mice models of renal cell and bladder carcinoma[3].

Animal Model:mCD16-/-hCD16A+ mice implanted with A498 renal cell carcinoma, 786-0 renal cell carcinoma, or HT-1197 bladder carcinoma cells (s.c.)[3]
Dosage:1 mg/kg, 5 mg/kg, 10 mg/kg
Administration:Intravenous injection; once weekly; 5 weeks
Result:Significantly inhibited tumor growth at doses of 1 mg/kg or greater with once weekly treatment.
Achieved a cytostatic response at 5 or 10 mg/kg until day 52, after which the average tumor volume of the 5 mg/kg treatment group remained near predose administration levels, whereas a nonsignificant trend toward relapse exhibited in the 10 mg/kg group.
References[1] Hińcza-Nowak K, et al. Immune Profiling of Medullary Thyroid Cancer-An Opportunity for Immunotherapy. Genes (Basel). 2021 Sep 28;12(10):1534. DOI:10.3390/genes12101534
[2] Chapoval, et al. Immune Checkpoints of the B7 Family. Part 2. Representatives of the B7 Family B7-H3, B7-H4, B7-H5, B7-H6, B7-H7, and ILDR2 and Their Receptors. Russ J Bioorg Chem 45, 321–334 (2019).
[3] Loo D, et al. Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity. Clin Cancer Res. 2012 Jul 15;18(14):3834-45. DOI:10.1158/1078-0432.CCR-12-0715
MGA271 Preparation Products And Raw materials
Tag:MGA271(1353485-38-7) Related Product Information
Panitumumab belimumab Tomuzotuximab guselkumab Siltuximab dupilumab Evinacumab Atezolizumab Drozitumab Solanezumab